John P. Mueller Email & Phone Number

Waltham, Ma

Waltham, Ma

Waltham, Ma

Key Individual Accountabilities; report directly to the Head of Infection Innovative Medicines• Drive delivery of a portfolio of inter-related clinical and pre-clinical phase antibacterial projects from lead optimization to Phase 2b with key internal functions and external stakeholders • Contribute to preparation of IND applications and interactions with the FDA• Accountability for the delivery of projects according to quality, time, budgets and resources• Design, develop and implement antibacterial disease area strategy• Develop and coordinate differentiated target product profiles• Drive future strategic direction in terms of unmet medical need and product differentiation based on a thorough assessment of potentially competitive products either in the market or in development• Foster and drive scientific innovation especially in the new field of pathogen-directed strategies• Develop external networks (KOLs, NGOs, health authorities, etc.) and increase external awareness of AstraZeneca Infection• Member of the Infection Leadership Team accountable for portfolio strategy and deliverables through POC/Ph2b• Present at Scientific Advisory Meetings, internal investment decisions and top levels of the company including the head of R&D and CEOKey Shared Accountabilities• Collaborate w/ commercial, marking and payer evidence to define reimbursement strategy• Evaluating and recommend product opportunities for in-licensing

Groton Laboratories

Antibacterials Research Unit, Biology Lead, Pfizer Pharmatherapeutics • Leadership and management of core research activities. Frontline interface between scientists and portfolio – report directly to CSO. Strategic, scientific and operational co-leader to ensure biology group is effectively staffed and operating against an endorsed set of small molecule and biological/immunotherapeutic research projects in support of the disease area strategy.• Scientific leadership across small and large molecule antibacterials focused on delivering differentiated therapeutic modalities for treatment of multi-drug resistant Gram-negative infections and biological (mAb) approaches for Pseudomonas aeruginosa and sepsis (anti-TLR4 mAbs)• Key point of contact for partner lines (Chemistry, Drug Safety, Technology, and Drug Metabolism, Pharm. Sci.), Scientific Advisory Board and external Key Opinion Leaders to ensure proper alignment and maximum effectiveness and efficiency in support of the pre-clinical research and candidate development through POC.• Accountable for evaluating and recommending technology and product opportunities for in-licensing/R&D collaborations. • Primary research interface with Business Unit colleagues in commercial, medical, marketing and clinical.• Line responsibility for 5 direct reports (4 Ph.D.) and 19 indirect reports.

Pfizer Groton Laboratories

• Strategic and tactical leadership for antibacterials biology group in close collaboration w/ medicinal chemistry, drug metabolism, drug safety and pharmaceutical sciences to maximize cross-functional synergies of multi-disciplinary teams. • Leadership on multi-disciplinary teams responsible for preclinical toxicology profiling, clinical planning, regulatory filings and clinical program execution for compounds resulting in three IND filings. • Member, Global AB Mgmt Team – responsible for improving cross-site efficiencies (Groton and Ann Arbor antibacterial teams), SOPs and best practices for TA processes.• Research lead for Antibacterials Disease Area Working Group comprised of commercial, medical and clinical colleagues responsible for crafting 5-10 year integrated strategic plan for senior management endorsement.• Leadership of cross-site working group to develop strategic and operational plan for antibacterial immunotherapies for serious hospital bacterial infections.• Strategic leadership on Elusys and PharmOptima collaboration research efforts; member collaborative steering committees.• Discovery rep for Global Diagnostics Team to ensure alignment of diagnostic and TA strategies.• People mgmt responsibilities for antibacterial biology (10 Ph.D. scientists; 28 indirect reports).

• Led team of four labs to validate targets, identify novel lead matter and advance Groton antibacterial portfolio form idea to clinical candidate.• Co-lead of Affinium (structural biology) collaboration, accountable for strategic, operational and scientific leadership of three site partnership (Groton, Ann Arbor and Affinium). Primary point of contact for all FTO related queries in setting research priorities for prosecution of the Affinium-Pfizer patent estate. • Managerial responsibility for Groton AB exploratory portfolio to achieve HTS and lead development TA goals.• People mgmt responsibilities for three laboratories (3 Ph.D. scientists/2 research scientists; 6 indirect reports).

Project leader, Target-based lead development program. First to deliver lead development program that originated from an HTS and first to be driven in large part by structural biology (X-ray/NMR) and biophysical components. • Co-leader Affinium collaboration – Coordinating roles and responsibilities of cross-site structural biology team, determine resources required for implementing, executing annual work plan, scientific database mgmt. across three sites (20 partners at Affinium in Toronto) and report progress to senior mgmt and steering committee.• Co-chair, Joint Pfizer-Affinium Working Team, multi-disciplinary team of scientists responsible for managing extensive target database (100) and technology platform. Responsibility for both operational and strategic plans across three sites (Pfizer Groton; Pfizer Ann Arbor and Affinium Pharma., Toronto) on behalf of the team. • Hygromycin A Project Team Coordinator - pre-clinical lead optimization program. Worked closely with Chemistry, ADME, and Drug Safety team counterpart to coordinate biological testing of compound analogs to bring forward a Gram-positive skin/skin structure clinical candidate.• Exploratory group leader - accountability for portfolio coordination to lead development to achieve annual TA goals. Accountable for evaluating, recommending and adopting new technologies (i.e., automated plate-based pharmacology, structure-based drug design, fragment-based screening). • Designed and directed Open Access Screening lab for identifying equipment and design of a state-of-the art plate-based centralized screening lab to support zone hit-to-lead chemistry campaigns. Responsible for status updates to site mgmt, global OASL team and roll-out plan to discovery biology.• Directed a lab of 3 research scientists dedicated to the determination of MOA of antibacterial compounds. Responsibilities included establishment of global target validation strategy.

Program Coordinator, Exploratory Project Team and Microcide Essential Genes Program – responsible for coordination and establishment of an antibacterials exploratory portfolio including target selection and validation. Laboratory responsible for conception and implementation of novel antibacterial target screen development for HTS including target validation (genetic & biochemical) in S. aureus and Enterococcus.• Leadership of Microbial Genomics Team – Responsible for implementing microbial genomics technology and genome analysis software applied to novel target identification. Currently coordinate, design and conduct studies with bioinformatics colleagues of public and proprietary bacterial genomic databases with laboratory microbial physiology and genetic investigations of novel antibacterial targets. • Leadership of Microcide collaboration – identification of chemical leads through a genetic potentiation whole cell screening screen platform (1999-2001).• Responsible for integrating structural biology group to enable structure-based drug design during lead generation and optimization.• Directed team of 3 scientists dedicated to the determination of mechanism of action and resistance emergence of antibacterial compounds. Led the design and execution of screening methods to address mechanism of action and resistance emergence studies on antibacterial compounds from target-based screens and medicinal chemistry programs.

• Team Leader, Multiple Sclerosis (MS) Program. Responsible for design, coordination and execution of research/preclinical efforts focused on antigen-specific immunotherapies for MS. Coordination of R&D work plan w/ NIH collaborators (Dr. Michael Lenardo) under CRADA to evaluate antigen-specific immunomodulators in a non-human primate model of MS. Clinical assay development.• Development of recombinant human proteins for preclinical analysis of antigen-specific therapies for diabetes.• Member, Transplantation Immunology Team. Development of immunotherapies to suppress cell-mediated rejection of discordant xenografts. Molecular cloning, expression and purification of soluble functional porcine adhesion and co-stimulatory molecules. Identification, characterization and humanization of blocking mAbs specific for porcine adhesion (VCAM)/co-stimulatory molecules (B7).• Supervised 2 B.S. level biologists.

Phd, Molecular Microbiology & Immunology

Bs, Microbiology